First test of SCTB35 for returning B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug called SCTB35 for people with relapsed or refractory B-cell non-Hodgkin lymphoma that is CD20-positive. It aims to find a safe dose and see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lymphoma must be CD20-positive and one of the listed types (like DLBCL, follicular lymphoma, or mantle cell lymphoma).
- The lymphoma must have come back, gotten worse, or not responded to at least one prior treatment that included an anti-CD20 therapy (like rituximab).
- You must have at least one tumor that can be measured on a scan (like a CT or MRI).
- You must be generally well enough to be up and about (ECOG performance status 0–2).
- Your heart, liver, kidney, and blood counts must meet minimum safety levels (e.g., hemoglobin > 9 g/dL, platelets > 75,000).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
This trial tests a new drug called SCTB35 combined with lenalidomide (a known cancer drug) in people whose follicular lymphoma (a type of blood cancer) has stopped responding to or come back after previous treatments. The combination may help shrink tumors and improve survival.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new drug called TRS005 for people with a specific type of lymphoma (CD20-positive DLBCL) that has come back or not responded to at least two prior treatments. It is for those who cannot have a stem cell transplant and aims to see if the drug can shrink tumors and help control the disease.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
Hear when a new Non-Hodgkin Lymphoma, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.